What is GSK Plc - ADR Annual Revenue?

GSK Plc - ADR Annual Revenue rose 3.46%, in the last year to $31,376 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

What is GSK Plc - ADR Annual Net Profit?

GSK Plc - ADR Annual Net Profit fell 47.75% in the last year to $2,575 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is GSK Plc - ADR Price to Earning Ratio?

GSK Plc - ADR Price to Earning Ratio is 23.57, higher than its sector PE ratio of 4.26.

What is GSK Plc - ADR Stock Price?

GSK Plc - ADR Stock Price fell 8.93% and underperformed its sector by 18.83% in the past year.

What is GSK Plc - ADR Quarterly Revenue?

GSK Plc - ADR Quarterly Revenue rose 0.81% YoY to $8,117 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

What is GSK Plc - ADR Quarterly Net profit?

GSK Plc - ADR Quarterly Net profit rose 18.29% YoY to $414 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is GSK Plc - ADR Debt to Equity Ratio?

GSK Plc - ADR Debt to Equity Ratio of 1.24 is higher than 1. This implies that company assets are financed through debt.

What is GSK Plc - ADR Return on Equity(ROE)?

GSK Plc - ADR Return on Equity(ROE) for the last financial year was 19.06%, in the normal range of 10% to 20%.

What is GSK Plc - ADR Mutual Fund Holding?

GSK Plc - ADR Mutual Fund Holding increased by 0.57% in the last quarter to 7.79.

What is GSK Plc - ADR Interest Coverage Ratio?

GSK Plc - ADR Interest Coverage Ratio is 6.43, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is GSK Plc - ADR Institutional Holding?

GSK Plc - ADR Institutional Holding increased by 1.74% in the last quarter to 16.69.

How is the GSK Plc - ADR today?

The GSK Plc - ADR today is trading in the down by -1.71% at 38.57.

How has GSK Plc - ADR performed historically?

The GSK Plc - ADR is currently trading down -1.71% on an intraday basis in the past week the index fell -2.33%. The index has been up 13.24% in the past quarter and fell -8.93% in the past year. You can view this in the overview section.

GSK Plc - ADR XNYS: GSK

GSK Plc - ADR Live Share Price Today, Share Analysis and Chart

Name: GSK Plc - ADR: Is Infosys Ltd. worth buying?
Item: GSK Plc - ADR
Rating: 1.6833195
Author: Trendlyne DVM scores

Await Turnaround

Download real time

38.57 -0.67 (-1.71%)

4.1M XNYS Volume

XNYS 24 Mar, 2025 5:30 PM (EDT)

GSK Plc - ADR Key Metrics

My Metrics

Default

Market Capitalization High in industry Unavailable in chosen country	78,469.5
PE TTM High in industry Unavailable in chosen country	23.6
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.5
Price to Book Below industry Median Unavailable in chosen country	3.5
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	16.7
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	0.8
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	3.5
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	18.3
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-47.7
Operating Profit Margin Qtr % High in industry Unavailable in chosen country	27.3
Operating Profit Margin TTM % High in industry Unavailable in chosen country	17.7
Piotroski Score High in industry Unavailable in chosen country	3
Rel Perf vs Sector quarter% Unavailable in chosen country	6
ROE Annual % High in industry Unavailable in chosen country	19.1
RoA Annual % High in industry Unavailable in chosen country	4.3

All financials are in GBP Million and price data in USD

Low Financial Strength

27.8 / 100

Mid Valuation

30.5 / 100

Technically Neutral

48.6 / 100

Await Turnaround These stocks are of poor quality, but mid-range financials and valuations. Their performance may improve based on financials, however our advise would be to be careful before buying these stocks. View Similar Embed DVM

1Yr Price target upside is 13%

8 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Sell Zone

67.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

GSK Plc - ADR Stock Price Analysis

Day Price Range -1.7% 1 Day return Unavailable in chosen country	38.6 (LTP) 38.538.9 LowHigh
Week Price Range -2.3% 1 Week return Unavailable in chosen country	38.6 (LTP) 38.540.5 LowHigh
Month Price Range 5.3% 1 Month return Unavailable in chosen country	38.6 (LTP) 36.740.8 LowHigh
52 Week Price Range -8.9% 1 Year return Unavailable in chosen country	38.6 (LTP) 31.745.9 LowHigh

View full Share Price History

GSK Plc - ADR Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

GSK Plc - ADR's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

1.6

Avg. Estimate

3.4

Low Estimate

3.4

High Estimate

3.4

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 119.4% in FY25

Consensus Recommendation

8 ANALYST Recommendations

HOLD

The consensus recommendation from 8 analysts for GSK Plc - ADR is HOLD

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

GSK Plc - ADR Stock Analysis

GSK Plc - ADR stock analysis with key metrics, changes, and trends.

GSK Plc - ADR Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$31,376 M	3.46%	positive	Annual Revenue rose 3.46%, in the last year to $31,376 M. Its sector's average revenue growth for the last fiscal year was 7.46%.
Annual Net Profit	$2,575 M	47.75%	negative	Annual Net Profit fell 47.75% in the last year to $2,575 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	23.57	-	negative	Price to Earning Ratio is 23.57, higher than its sector PE ratio of 4.26.
Stock Price	$38.57	-8.93%	negative	Stock Price fell 8.93% and underperformed its sector by 18.83% in the past year.
Quarterly Revenue	$8,117 M	0.81%	positive	Quarterly Revenue rose 0.81% YoY to $8,117 M. Its sector's average revenue growth YoY for the quarter was 5.96%.
Quarterly Net profit	$414 M	18.29%	positive	Quarterly Net profit rose 18.29% YoY to $414 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Debt to Equity Ratio	1.24	-	negative	Debt to Equity Ratio of 1.24 is higher than 1. This implies that company assets are financed through debt.
Return on Equity(ROE)	19.06 %	19.06%	neutral	Return on Equity(ROE) for the last financial year was 19.06%, in the normal range of 10% to 20%.
Mutual Fund Holding	7.79 %	0.57%	positive	Mutual Fund Holding increased by 0.57% in the last quarter to 7.79.
Interest Coverage Ratio	6.43	-	positive	Interest Coverage Ratio is 6.43, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Institutional Holding	16.69 %	1.74%	positive	Institutional Holding increased by 1.74% in the last quarter to 16.69.

VIEW LESS

Loading data..

GSK Plc - ADR - Company Profile

What does GSK Plc - ADR do?

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

228 K

2024

Gross Remuneration

Year

GSK Plc - ADR Live Share Price Today, Share Analysis and Chart

GSK Plc - ADR Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Check Before You Buy

Check P/E Buy Sell Zone

GSK Plc - ADR Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

GSK Plc - ADR Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

GSK Plc - ADR's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to grow by 119.4% in FY25

Consensus Recommendation

The consensus recommendation from 8 analysts for GSK Plc - ADR is HOLD

GSK Plc - ADR Stock Analysis

GSK Plc - ADR stock analysis with key metrics, changes, and trends.

Annual Revenue rose 3.46%, in the last year to $31,376 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit fell 47.75% in the last year to $2,575 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is 23.57, higher than its sector PE ratio of 4.26.

Stock Price fell 8.93% and underperformed its sector by 18.83% in the past year.

Quarterly Revenue rose 0.81% YoY to $8,117 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit rose 18.29% YoY to $414 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Debt to Equity Ratio of 1.24 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE) for the last financial year was 19.06%, in the normal range of 10% to 20%.

Mutual Fund Holding increased by 0.57% in the last quarter to 7.79.

Interest Coverage Ratio is 6.43, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding increased by 1.74% in the last quarter to 16.69.

GSK Plc - ADR - Company Profile

What does GSK Plc - ADR do?

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK Plc - ADR Management structure

Dame Emma N. Walmsley

Executive Director, Chief Executive Officer

Ms. Julie Brown

Executive Director, Chief Financial Officer

Mrs. Victoria Anne Whyte

Company Secretary

GSK Plc - ADR Board of directors

Sir Jonathan Richard Symonds CBE

Non-Executive Director, Chairman

Dr. Hal V Barron

Non-Executive Director

Mr. Charles A. Bancroft

Non-Executive Director, Senior Independent Director

Dr. Harry C Dietz

Non-Executive Director

Dr. Anne Beal